Key result
Oral anticoagulants reduce nonvalvular AF stroke risk ~67%, with NOACs lowering intracranial bleeding versus warfarin.
Why the study?
Although NOACs reduce stroke risk in nonvalvular AF, whether their use is beneficial for stroke prevention in other patient populations remains an open question.
Does NOAC use prevent stroke in patient populations with emerging cardioembolic risk entities?
Does NOAC use prevent stroke in patient populations with emerging cardioembolic risk entities?
This viewpoint discusses the potential benefits of NOACs for stroke prevention in emerging cardioembolic risk populations beyond nonvalvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports exploring NOACs beyond nonvalvular AF; leaves open dedicated trials in emerging cardioembolic populations.
Atrial fibrillation (AF) increases the risk of ischemic stroke, accounts for about one quarter of all ischemic strokes worldwide, and is associated with a substantial morbidity and mortality.1 Oral anticoagulation can reduce the stroke risk in nonvalvular AF by two thirds by using vitamin K antagonists or non‐vitamin K‐dependent oral anticoagulants (NOACs), which are now preferentially used, as NOACs were superior to warfarin in reducing the risk of intracranial bleeding.1 Whether NOAC use is beneficial in stroke prevention in other patient populations is discussed in this viewpoint, based on ongoing or published randomized controlled trials (RCTs).
No takes yet. Share an insight, caveat, or question.
Wachter et al. (2024) conducted a review in Atrial fibrillation. Non-vitamin K-dependent oral anticoagulants (NOACs) vs. Vitamin K antagonists (warfarin) was evaluated on Stroke risk and intracranial bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: